Clinical neurobiology

Share on

Group leader:  Antonio Bertolotto

Clinical neurobiology

Publications

2020

Montarolo F*, Perga S, Tessarolo C, Spadaro M, Martire S, Bertolotto A (2020)  TNFAIP3 Deficiency Affects Monocytes, Monocytes-Derived Cells and Microglia in Mice.  International Journal of Molecular Science21, 2830. DOI:10.3390/ijms21082830

Valsecchi V*, Boido M*, Montarolo F, et al.  The transcription factor Nurr1 is up-regulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice  [published online ahead of print, 2020 Mar 18]. Dis Model Mech. 2020;dmm.043513. doi:10.1242/dmm.043513 - *co-authors

2019

Spadaro M, Montarolo F, Martire S., Frezet F, Bruno S, Grometto A, Perga S, Brescia F, Valentino P, Marnetto F, Botta G, Marozio L, Bertolotto A.  Pregnancy: a powerful transient immunosuppressive phenomenon in Multiple Sclerosis women , Poster presentation at the 2019 FISM Congress, Rome (Italy).

Montarolo F, Martire S, Perga S and Bertolotto A.  NURR1 Impairment in Multiple Sclerosis.  Int. J. Mol. Sci. 2019, 20, 4858; doi:10.3390/ijms20194858.

Montarolo F, Perga S, Tessarolo C, Spadaro M, Martire S, Bertolotto A.  TNFAIP3 in circulating and parenchymal myeloid lineage critically controls monocytes, monocytes-derived cells and microglia.  Journal of Neuroinflammation (submitted).

Giordano A, Testa S, Bassi M, Cilia S, Bertolotto A, Quartuccio ME, Pietrolongo E, Falautano M, Grobberio M, Niccolai C, Allegri B, Viterbo RG, Confalonieri P, Giovannetti AM, Cocco E, Grasso MG, Lugaresi A, Ferriani E, Nocentini U, Zaffaroni M, De Livera A, Jelinek G, Solari A, Rosato R.  Assessing measurement invariance of MSQOL-54 across Italian and English versions. Qual Life Res . 2019 Nov 9. doi: 10.1007/s11136-019-02352-0. [Epub ahead of print]

Acknowledgement to Authors, Referees and Readers 2019.
Sabbagh M, Bertolotto A. Neurol Ther. 2019 Dec;8(2):513-515. doi: 10.1007/s40120-019-00163-6. No abstract available.

Spadaro M, Martire S, Marozio L, Mastromauro D, Montanari E, Perga S, Montarolo F, Brescia F, Balbo A, Botta G, Benedetto C, Bertolotto A.  Immunomodulatory Effect of Pregnancy on Leukocyte Populations in Patients With Multiple Sclerosis: A Comparison of Peripheral Blood and Decidual Placental Tissue .
Front Immunol. 2019 Aug 16;10:1935. doi: 10.3389/fimmu.2019.01935. eCollection 2019.

Montarolo F, Martire S, Perga S, Spadaro M, Brescia I, Allegra S, De Francia S, Bertolotto A.  NURR1 deficiency is associated to ADHD-like phenotypes in mice . Transl Psychiatry. 2019 Aug 27;9(1):207. doi: 10.1038/s41398-019-0544-0.

Romano S, Ferraldeschi M, Bagnato F, Mechelli R, Morena E, Caldano M, Buscarinu MC, Fornasiero A, Frontoni M, Nociti V, Mirabella M, Mayer F, Bertolotto A, Pozzilli C, Vanacore N, Salvetti M, Ristori G.  Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority.  Front Neurol. 2019 Jul 16;10:695. doi: 10.3389/fneur.2019.00695. eCollection 2019.

Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV.  Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.  Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019. Review.

Sabbagh M, Bertolotto A.  Neurology and Therapy: Looking Back on 2018 and Forward to 2019.
Neurol Ther. 2019 Jun;8(1):1-3. doi: 10.1007/s40120-019-0126-3. Epub 2019 Jan 30. No abstract available.

2018

Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S. Italian PML Group.  Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.  2018 ; J Neurol Neurosurg Psychiatry. 2018 Nov 2. IF 7.14 R=36/336

Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group.  No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month realworld study.  J Neurol. 2018 Sep 26. IF=3.78

Marcinnò A, Marnetto F, Valentino P, Martire S, Balbo A, Drago A, Leto M, Capobianco M, Panzica G, Bertolotto, A.  Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders.  Neurol Neuroimmunol Neuroinflamm. 2018 Sep 13;5(6) IF= 6.429; R= 36/336

Bo M, Charrier L, Bartalini S, Benvenuti M, Oggero A, Ulivelli M, Gabbrielli M, Bertolotto A, Gianino MM.  Access to social security benefits among multiple sclerosis patients in Italy: A cross-sectional study Mult Scler Relat Disord.  2018 Aug; 24:107-112. IF=4.84¸ R=clinical neurology 91/336

Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La Gioia S, Cavarretta R, Mantero V, Costantini G, D'Ambrosio V, Zaffaroni M, Ghezzi A, Perini P, Rossi S, Bertolotto A, Rottoli MR, Rovaris M, Balgera R, Cavalla P, Montomoli C, Bergamaschi R.  Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study .  J Neurol. 2018 Aug; 265(8):1850-1859. IF= 3.78

Rosato R, Testa S, Bertolotto A, Scavelli F, Giovannetti AM, Confalonieri P, Patti F, Chisari CG, Lugaresi A, Pietrolongo E, Grasso MG, Rossi I, Toscano A, Loera B, Giordano A, Solari A.  eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54 . Mult Scler. 2018 May IF= 5.28 R=69/336

Perga S, Martire S, Montarolo F, Giordani I, Spadaro M, Bono G, Corvisieri S, Messuti I, Panzica G, Orlandi F, Bertolotto A.  The Footprints of Poly-Autoimmunity: Evidence for Common Biological Factors Involved in Multiple Sclerosis and Hashimoto's Thyroiditis.  Front Immunol. 2018 Feb 20; 9:311. IF= 6.429; R= 24/194

Carletto S, Borghi M, Scavelli F, Francone D, Perucchini ML, Cavallo M, Pagnini F, Bertolotto A, Oliva F, Ostacoli L.  Prevalence of Posttraumatic Stress Disorder in Patients With Multiple Sclerosis.  J Nerv Ment Dis. 2018 Feb;206(2):149-151. IF= 1.94 R= 167/487

Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents : A Baroncini D, Zaffaroni M, Moiola L, Lorefice L, Fenu G, Iaffaldano P, Simone M, Fanelli F, Patti F, D'Amico E, Capobianco M, Bertolotto A, Gallo P, Margoni M, Miante S, Milani N, Amato MP, Righini I, Bellantonio P, Scandellari C, Costantino G, Scarpini E, Bergamaschi R, Mallucci G, Comi G, Ghezzi A; iMED Registry and Gruppo di Studio SM-Società Italiana di Neurologia. multicentre, Italian, retrospective, observational study. Mult Scler. 2018 Jan 1 IF=5.28 R=69/336

Correction to: Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.  Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G. Neurol Sci. 2018 Feb;39(2):395 IF=1.74; R=clinical neurology 169/336

Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia.  Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A. J Neurovirol. 2018 Feb;24(1):132-136 1 IF=3.22 R= 58/336

2017

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468.

Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A. Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. Neurol Neuroimmunol Neuroinflamm 2017;4:e317; doi: 10.1212/ NXI.0000000000000317  PMID: 28054001

Clemente N, Comi C, Raineri D, Cappellano G, Vecchio D, Orilieri E, Gigliotti CL, Boggio E, Dianzani C, Sorosina M, Martinelli-Boneschi F, Caldano M, Bertolotto A, Ambrogio L, Sblattero D, Cena T, Leone M, Dianzani U and Chiocchetti A (2017)  Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Front. Immunol. 8:321. doi: 10.3389/fimmu.2017.00321

Melillo F, Di Sapio A, Martire S, Malentacchi M, Matta M, Bertolotto A. Computerized posturography is more sensitive than clinical Romberg Test in detecting postural control impairment in minimally impaired Multiple Sclerosis patients. Mult Scler and Rel Dis, 14:51-55, 2017 ISSN 2211-0348, http://doi.org/10.1016/j.msard.2017.03.008 .

Malucchi S, Capobianco M, Lo Re M, Malentacchi M, di Sapio A, Matta M, Sperli F, Bertolotto A  High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. Neurol Ther. 2017 Jun;6(1):145-152. doi: 10.1007/s40120-016-0058-0. Epub 2016 Dec 3. PMID: 27915429

Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group. Collaborators: Amato MP, Bandini F, Bertolotto A, Brescia-Morra V, Cavaletti G, Cavalla P, Capobianco M, Clerico M, D'Aleo G, de Riz M, Deotto L, Durelli L, Falcini M, Ferrari E, Fusco ML, Gasperini C, Gerevini S, Ghezzi A, Grimaldi L, Guidotti M, Lugaresi A, Naldi P, Moiola L, Perrone P, Pizzorno M, Pozzilli C, Rezzonico M, Rovaris M, Salemi G, Salvetti M, Santuccio G, Scarpini E, Sessa E, Solaro C, Tabiadon G, Tortorella C, Trojano M  No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740 PMID: 28228569

Marnetto F, Valentino P, Caldano M, Bertolotto A. Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients.   J Immunol Methods. 2017 Mar 12. pii: S0022-1759(16)30395-7. doi: 10.1016/j.jim.2017.03.008. [Epub ahead of print] PMID: 28300540

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry. Prognostic indicators in pediatric clinically isolated syndrome. Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938. PMID: 28439957

Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, Bertolotto A Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients Clin Immunol 181 (2017) 83–88 doi: 10.1016/j.clim.2017.06.006. PMID: 28642148

Gils A, Bertolotto A, Mulleman D, Bejan-Angoulvant T, Declerck PJ. Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. Ther Drug Monit. 2017 Aug;39(4):308-315. doi: 10.1097/FTD.0000000000000385. PMID: 28230618

Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-Angoulvant T, Pascual-Salcedo D, Mulleman D. Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. Ther Drug Monit. 2017 Aug;39(4):339-343. doi: 10.1097/FTD.0000000000000410. PMID: 28486309

Caldano M, Raoul W, Rispens T, Bertolotto A. Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents.   Ther Drug Monit. 2017 Aug;39(4):350-355. doi: 10.1097/FTD.0000000000000393. PMID: 28328761

2016

Bertolotto A, Malentacchi M, Capobianco M, di Sapio A, Malucchi S, Motuzova Y, Pulizzi A, Berchialla P, Sperli F  The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practice Cephalalgia 2016, 36: 131-138, doi:10.1177/0333102415583983

Carletto S, Borghi M, Francone D, Scavelli F, Bertino G, Cavallo M, Malucchi S, Bertolotto A, Oliva F, Ostacoli L. The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trial. BMC Neurol. 2016 Jan 13;16(1):7. doi: 10.1186/s12883-016-0528-0. ISSN: 14712377 PMID: 26757728

Martire S, Navone ND, Montarolo F, Perga S, Bertolotto A. A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients. J Neuroimmunol. 2016 Mar 15;292:34-9. doi: 10.1016/j.jneuroim.2016.01.010. Epub 2016 Jan 16. PMID: 26943956

Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075-84. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28

Rosato R, Testa S, Bertolotto A, Confalonieri P, Patti F, Lugaresi A, Grasso MG, Toscano A, Giordano A, Solari A. Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. PLoS One. 2016 Apr 14;11(4):e0153466. doi: 10.1371/journal.pone.0153466. eCollection 2016. PMID: 27078146

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC. Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr PMID: 26894205

Troni W, Melillo F, Bertolotto A, Malucchi S, Capobianco M, Sperli F, Di Sapio A.  Normative Values for Intertrial Variability of Motor Responses to Nerve Root and Transcranial Stimulation: A Condition for Follow-Up Studies in Individual Subjects PLoS One. 2016 May 16;11(5):e0155268. doi: 10.1371/journal.pone.0155268. eCollection 2016. PMID: 27182973

Borghi M, Carletto S, Ostacoli L, Scavelli F, Pia L, Pagani M, Bertolotto A, Malucchi S, Signori A, Cavallo M. Decline of Neuropsychological Abilities in a Large Sample of Patients with Multiple Sclerosis: A Two-Year Longitudinal Study. Front Hum Neurosci. 2016 Jun 8;10:282. doi: 10.3389/fnhum.2016.00282. eCollection 2016. PMID: 27375468

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H. PML risk stratification using anti-JCV antibody index and L-selectin.  Mult Scler. 2016 Jul;22(8):1048-1060. Epub 2015 Oct 2. PMID: 26432858